

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

Brilliant Violet 650(TM) anti-human CD4

RRID:AB_2632791

Type: Antibody

Proper Citation

BioLegend Cat# 300536, RRID:AB_2632791

Antibody Information

URL: http://antibodyregistry.org/AB_2632791

Proper Citation: BioLegend Cat# 300536, RRID:AB_2632791

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 650(TM) anti-human CD4

Description: This monoclonal targets CD4

Target Organism: human

Clone ID: Clone RPA-T4

Antibody ID: AB_2632791

Vendor: BioLegend

Catalog Number: 300536

Alternative Catalog Numbers: 300535

Record Creation Time: 20231110T034723+0000

Record Last Update: 20260829T013732+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650(TM) anti-human CD4.

No alerts have been found for Brilliant Violet 650(TM) anti-human CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Oh MS, et al. (2025) Characteristics of a CCL21 Gene-Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non-Small Cell Lung Cancer. *Molecular cancer therapeutics*, 24(2), 286.

Chauhan SKS, et al. (2025) Protocol for optimized mononuclear cell isolation from liver and tumor tissue using mechanical or enzymatic digestion. *STAR protocols*, 7(1), 104289.

Kögl T, et al. (2024) Patients and mice with deficiency in the SNARE protein SYNTAXIN-11 have a secondary B cell defect. *The Journal of experimental medicine*, 221(7).

Kirosingh AS, et al. (2023) Malaria-specific Type 1 regulatory T cells are more abundant in first pregnancies and associated with placental malaria. *EBioMedicine*, 95, 104772.

Baerends EAM, et al. (2023) SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection. *iScience*, 26(9), 107621.

Santegoets SJ, et al. (2023) The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival. *Cell reports. Medicine*, 4(11), 101262.

van der Ploeg K, et al. (2022) TNF- γ + CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. *Cell reports. Medicine*, 3(6), 100640.

Goenka A, et al. (2021) Young infants exhibit robust functional antibody responses and restrained IFN- γ production to SARS-CoV-2. *Cell reports. Medicine*, 2(7), 100327.

Wang J, et al. (2020) Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary Atresia. *Cell*, 183(7), 1867.